TALS

Talaris Therapeutics, Inc. [TALS] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

TALS Stock Summary

In the News

TALS Financial details

Company Rating
-
Market Cap
116.44M
Income
-57.66M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
1.51
Dividend %
55.58%
Employees
84
Optionable
No
Shortable
Yes
Earnings
08 Nov 2023
P/E
-1.67
Forward P/E
-
PEG
0.99
P/S
-
P/B
0.77
P/C
-
P/FCF
-1.94
Quick Ratio
15.02
Current Ratio
15.41
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-13.74
EPS next Y
-
EPS next Q
-
EPS this Y
0.79%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-53.01%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-43%
ROE
-40%
ROC
-0.54%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.89-3.29
52W High
-
52W Low
-
RSI
-
Rel Volume
2.12
Avg Volume
142.92K
Volume
303.48K
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-3.55%
-
-
-
-
Beta
2.1789
-
-
Volatility
0.04%, 0.04%
Prev Close
0%
Price
2.72
Change
-2.16%

TALS Financial Performance

TALS Dividend History

TALS Frequently Asked Questions

What is Talaris Therapeutics, Inc. stock symbol ?

Talaris Therapeutics, Inc. is a US stock , located in Louisville of Ky and trading under the symbol TALS

What is Talaris Therapeutics, Inc. stock quote today ?

Talaris Therapeutics, Inc. stock price is $2.72 today.

Is Talaris Therapeutics, Inc. stock public?

Yes, Talaris Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
FXAIX
VFINX
V
VTSAX
GOOG
Same Sector
EYEN
TRIL.TO
MITI
000638.SZ
COX.PA
Check Those
IMGN
EUFN
LSTK
NORBTEAEXP.NS
0018.HK
Similar Market Cap
MCAA
EXV7.DE
SOLI.L
0403.HK
CSMXCP.SW

Company Profile

Healthcare Biotechnology
  • Volume Average 142.92K
  • Market Capitalization 116.44M
  • Employee 84
  • CEO Ms. Mary Kay Fenton
  • Headquarters Louisville,KY,US
  • IPO Date 2021-05-07
  • Website https://talaristx.com

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.